WO2004056337A3 - Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats - Google Patents

Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats Download PDF

Info

Publication number
WO2004056337A3
WO2004056337A3 PCT/US2003/040584 US0340584W WO2004056337A3 WO 2004056337 A3 WO2004056337 A3 WO 2004056337A3 US 0340584 W US0340584 W US 0340584W WO 2004056337 A3 WO2004056337 A3 WO 2004056337A3
Authority
WO
WIPO (PCT)
Prior art keywords
active agents
oral dosage
gelatin capsule
dosage forms
therapeutically active
Prior art date
Application number
PCT/US2003/040584
Other languages
French (fr)
Other versions
WO2004056337A2 (en
Inventor
Grant L Schoenhard
Original Assignee
Pain Therapeutics
Grant L Schoenhard
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pain Therapeutics, Grant L Schoenhard filed Critical Pain Therapeutics
Priority to AU2003301121A priority Critical patent/AU2003301121A1/en
Priority to CA002510465A priority patent/CA2510465A1/en
Priority to EP03813786A priority patent/EP1572164A2/en
Publication of WO2004056337A2 publication Critical patent/WO2004056337A2/en
Publication of WO2004056337A3 publication Critical patent/WO2004056337A3/en
Priority to AU2010236049A priority patent/AU2010236049A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core

Abstract

The present invention relates to oral dosage form with active agents in controlled release cores and in immediate release gelatin capsule coats.
PCT/US2003/040584 2002-12-18 2003-12-18 Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats WO2004056337A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2003301121A AU2003301121A1 (en) 2002-12-18 2003-12-18 Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats
CA002510465A CA2510465A1 (en) 2002-12-18 2003-12-18 Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats
EP03813786A EP1572164A2 (en) 2002-12-18 2003-12-18 Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats
AU2010236049A AU2010236049A1 (en) 2002-12-18 2010-10-27 Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43483902P 2002-12-18 2002-12-18
US60/434,839 2002-12-18

Publications (2)

Publication Number Publication Date
WO2004056337A2 WO2004056337A2 (en) 2004-07-08
WO2004056337A3 true WO2004056337A3 (en) 2004-08-19

Family

ID=32682116

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/040584 WO2004056337A2 (en) 2002-12-18 2003-12-18 Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats

Country Status (5)

Country Link
US (5) US20040224020A1 (en)
EP (1) EP1572164A2 (en)
AU (2) AU2003301121A1 (en)
CA (1) CA2510465A1 (en)
WO (1) WO2004056337A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8133507B2 (en) 2002-12-13 2012-03-13 Durect Corporation Oral drug delivery system
US9555113B2 (en) 2013-03-15 2017-01-31 Durect Corporation Compositions with a rheological modifier to reduce dissolution variability

Families Citing this family (137)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050148101A1 (en) * 1999-01-23 2005-07-07 Bamdad Cynthia C. Interaction of colloid-immobilized species with species on non-colloidal structures
US6428809B1 (en) * 1999-08-18 2002-08-06 Microdose Technologies, Inc. Metering and packaging of controlled release medication
US20040122090A1 (en) * 2001-12-07 2004-06-24 Lipton Stuart A. Methods for treating neuropsychiatric disorders with nmda receptor antagonists
US20030004177A1 (en) * 2001-05-11 2003-01-02 Endo Pharmaceuticals, Inc. Abuse-resistant opioid dosage form
US20070087048A1 (en) * 2001-05-31 2007-04-19 Abrams Andrew L Oral dosage combination pharmaceutical packaging
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
US20040253310A1 (en) 2001-09-21 2004-12-16 Gina Fischer Morphine polymer release system
US20040234602A1 (en) 2001-09-21 2004-11-25 Gina Fischer Polymer release system
EP1492511B3 (en) 2002-04-09 2012-05-02 Flamel Technologies Oral pharmaceutical formulation in the form of aqueous suspension for modified release of active principle(s)
WO2004071423A2 (en) * 2003-02-05 2004-08-26 Euro-Celtique S.A. Methods of administering opioid antagonists and compositions thereof
ES2360102T3 (en) 2003-03-26 2011-05-31 Egalet A/S SYSTEM FOR CONTROLLED RELEASE OF MORPHINE.
US20040202717A1 (en) 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
KR100732199B1 (en) * 2003-07-31 2007-06-25 모리나가 뉴교 가부시키가이샤 Masticatable capsule and process for producing the same
US20050158382A1 (en) * 2003-09-26 2005-07-21 Evangeline Cruz Controlled release formulations of opioid and nonopioid analgesics
MXPA06003450A (en) 2003-09-26 2006-08-31 Johnson & Johnson Drug coating providing high drug loading and methods for providing the same.
US20050226929A1 (en) * 2004-04-12 2005-10-13 Jianbo Xie Controlled release opioid analgesic formulation
HUE037643T2 (en) 2004-06-12 2018-09-28 Collegium Pharmaceutical Inc Abuse-deterrent drug formulations
US20060002999A1 (en) * 2004-06-17 2006-01-05 Forest Laboratories, Inc. Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane
US9308164B2 (en) * 2004-06-30 2016-04-12 Sovereign Pharmaceuticals, Llc Hyoscyamine dosage form
US8541026B2 (en) 2004-09-24 2013-09-24 Abbvie Inc. Sustained release formulations of opioid and nonopioid analgesics
MXPA04009698A (en) * 2004-10-04 2006-04-05 Maria Elena Garcia Armenta Solid pharmaceutical formulations comprising diacereine and meloxicam.
US7619007B2 (en) * 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
CA2588296A1 (en) 2004-11-24 2006-06-01 Neuromolecular Pharmaceuticals, Inc. Composition comprising an nmda receptor antagonist and levodopa and use thereof for treating neurological disease
US8226987B2 (en) * 2005-02-22 2012-07-24 Zoorob George K Herbal preparation to relieve inflammation and smooth muscle contraction
US20070053868A1 (en) 2005-03-08 2007-03-08 Banner Pharmacaps, Inc. Solvent system for enhancing the solubility of pharmaceutical agents
EP1879586A1 (en) * 2005-03-10 2008-01-23 Sciele Pharma, Inc. Nutritional preparations comprising folates and essential fatty acids
US20060217385A1 (en) * 2005-03-10 2006-09-28 Edwards John B Nutritional preparations
WO2006121560A2 (en) 2005-04-06 2006-11-16 Adamas Pharmaceuticals, Inc. Methods and compositions for treatment of cns disorders
US8394812B2 (en) 2005-08-24 2013-03-12 Penwest Pharmaceuticals Co. Sustained release formulations of nalbuphine
PT1931315E (en) 2005-08-24 2014-01-03 Endo Pharmaceuticals Inc Sustained release formulations of nalbuphine
US7861728B2 (en) * 2006-02-10 2011-01-04 R.J. Reynolds Tobacco Company Smokeless tobacco composition having an outer and inner pouch
CN101309675A (en) * 2005-10-14 2008-11-19 微量技术有限公司 Oral dosage combination pharmaceutical packaging
DE102005054943A1 (en) * 2005-11-17 2007-05-24 Gelita Ag Process for producing a hollow profile based on a crosslinked, gelatin-containing material and implants in the form of hollow profiles
US8022054B2 (en) 2005-11-28 2011-09-20 Marinus Pharmaceuticals Liquid ganaxolone formulations and methods for the making and use thereof
US20070148248A1 (en) * 2005-12-22 2007-06-28 Banner Pharmacaps, Inc. Gastric reflux resistant dosage forms
US7810507B2 (en) 2006-02-10 2010-10-12 R. J. Reynolds Tobacco Company Smokeless tobacco composition
EP1988886A1 (en) * 2006-02-13 2008-11-12 Intelgenx Corporation Delayed release pharmaceutical oral dosage form and method of making same
FR2897267A1 (en) * 2006-02-16 2007-08-17 Flamel Technologies Sa MULTIMICROPARTICULAR PHARMACEUTICAL FORMS FOR PER OS ADMINISTRATION
US8784886B2 (en) * 2006-03-09 2014-07-22 GlaxoSmithKline, LLC Coating capsules with active pharmaceutical ingredients
EP2081550B2 (en) 2006-03-09 2021-05-26 Reliant Pharmaceuticals, Inc. Coating capsules with active pharmaceutical ingredients
US7294350B2 (en) * 2006-03-21 2007-11-13 Marraccini Philip A Healing powder and method of use thereof
US20070253927A1 (en) * 2006-04-13 2007-11-01 Gwenaelle Jegou Cosmetic compositions comprising at least one dielectrophile monomer and at least one radical initiator
EP2046397A2 (en) * 2006-07-19 2009-04-15 SmithKline Beecham Corporation Method for radiolabeling formulations for gamma scintigraphy assesment
US8765178B2 (en) 2006-07-19 2014-07-01 Watson Laboratories, Inc. Controlled release formulations and associated methods
WO2008011596A2 (en) * 2006-07-21 2008-01-24 Lab International Srl Hydrophilic abuse deterrent delivery system
EP2091515B1 (en) * 2006-11-21 2014-06-04 McNeil-PPC, Inc. Modified release analgesic suspensions
EP2101735A2 (en) * 2006-11-28 2009-09-23 Marinus Pharmaceuticals, Inc. Nanoparticulate formulations and methods for the making and use thereof
US20080176927A1 (en) * 2007-01-19 2008-07-24 Optimer Pharmaceuticals, Inc. Compositions of stable tiacumicins
WO2008136917A1 (en) * 2007-05-04 2008-11-13 Troy Technology Corporation, Inc. Water-based antimicrobially active, dispersion concentrates
US7652048B2 (en) * 2007-05-04 2010-01-26 Troy Corporation Water-based, antimicrobially active, dispersion concentrates
AU2008258596B2 (en) 2007-06-04 2013-02-14 Egalet Ltd Controlled release pharmaceutical compositions for prolonged effect
US20080306132A1 (en) * 2007-06-07 2008-12-11 Praveen Hiremath Novel oral compositions of carporen
US9833510B2 (en) * 2007-06-12 2017-12-05 Johnson & Johnson Consumer Inc. Modified release solid or semi-solid dosage forms
US20170042821A1 (en) * 2007-07-01 2017-02-16 Vitalis Llc Combination tablet with chewable outer layer
US8404275B2 (en) 2007-07-01 2013-03-26 Vitalis Llc Combination tablet with chewable outer layer
EP2377413B1 (en) 2007-07-23 2017-03-01 R.J. Reynolds Tobacco Company Smokeless tobacco compositions and methods for treating tobacco for use therein
US20090087483A1 (en) * 2007-09-27 2009-04-02 Sison Raymundo A Oral dosage combination pharmaceutical packaging
US8439033B2 (en) 2007-10-09 2013-05-14 Microdose Therapeutx, Inc. Inhalation device
CA2706658A1 (en) 2007-12-06 2009-06-18 Durect Corporation Methods useful for the treatment of pain, arthritic conditions or inflammation associated with a chronic condition
EP2234711B1 (en) * 2008-01-25 2017-11-01 RJ Reynolds Tobacco Company Process for manufacturing breakable capsules useful in tobacco products
US9226907B2 (en) 2008-02-01 2016-01-05 Abbvie Inc. Extended release hydrocodone acetaminophen and related methods and uses thereof
EP2262367A4 (en) * 2008-03-08 2011-04-20 Theraquest Biosciences Inc Oral pharmaceutical compositions of buprenorphine and method of use
US8372432B2 (en) 2008-03-11 2013-02-12 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
WO2009151498A2 (en) * 2008-03-28 2009-12-17 Forest Laboratories Holdings Limited Memantine formulations
ES2563061T3 (en) * 2008-04-28 2016-03-10 Zogenix, Inc. New formulations for the treatment of migraine
EP2564833B1 (en) * 2008-07-28 2017-12-20 Takeda Pharmaceutical Company Limited Photostabilized pharmaceutical composition
US20100062057A1 (en) * 2008-09-10 2010-03-11 Pronova BioPharma Norge AS. Formulation
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
HUE032368T2 (en) * 2008-11-13 2017-09-28 Nogra Pharma Ltd Antisense compositions and methods of making and using same
PL2378883T3 (en) * 2008-12-04 2016-06-30 Intec Pharma Ltd Zaleplon gastroretentive drug delivery system
CA2750144C (en) 2008-12-31 2016-10-25 Upsher-Smith Laboratories, Inc. Opioid-containing oral pharmaceutical compositions and methods
NZ594207A (en) 2009-02-06 2013-03-28 Egalet Ltd Immediate release composition resistant to abuse by intake of alcohol
EP3045043B1 (en) * 2009-02-26 2020-04-29 Relmada Therapeutics, Inc. Extended release oral pharmaceutical compositions of 3-hydroxy-n-methylmorphinan and method of use
EP2445487A2 (en) 2009-06-24 2012-05-02 Egalet Ltd. Controlled release formulations
BRPI1016013A2 (en) * 2009-06-29 2016-04-26 Mcneil Ppc Inc pharmaceutical tablet containing a capsule filled with liquid.
US20110003655A1 (en) * 2009-07-01 2011-01-06 Chernick Mark J Segmented High-Bounce Toy Water Ball
US20120142720A1 (en) * 2009-07-02 2012-06-07 Kempharm, Inc. Phenylethanoic Acid, Phenylpropanoic Acid and Phenylpropenoic Acid Conjugates and Prodrugs of Hydrocodone, Methods of Making and Use Thereof
US8464726B2 (en) 2009-08-24 2013-06-18 R.J. Reynolds Tobacco Company Segmented smoking article with insulation mat
EP2477610A1 (en) 2009-09-17 2012-07-25 Upsher-Smith Laboratories, Inc. A sustained-release product comprising a combination of a non-opioid amine and a non-steroidal anti -inflammatory drug
EP2506709B2 (en) * 2009-12-02 2019-10-09 Adamas Pharmaceuticals, Inc. Amantadine compositions and methods of use
US10668060B2 (en) 2009-12-10 2020-06-02 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
US8597681B2 (en) * 2009-12-22 2013-12-03 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
CN104338219B (en) 2010-01-05 2017-10-24 微剂量治疗技术公司 inhalation device and method
US8486013B2 (en) * 2010-03-18 2013-07-16 Biotronik Ag Balloon catheter having coating
US20110236536A1 (en) * 2010-03-26 2011-09-29 Philip Morris Usa Inc. Method and composition for long lasting flavor delivery system
WO2011126327A2 (en) * 2010-04-09 2011-10-13 Hyundai Pharm Co., Ltd. Pharmaceutical composition with controlled-release properties comprising mosapride or levodropropizine, and preparing method thereof
JP5669837B2 (en) * 2010-06-16 2015-02-18 帝人ファーマ株式会社 Controlled release nucleated tablets
US10028520B2 (en) 2010-09-02 2018-07-24 R.J. Reynolds Tobacco Company Apparatus for manufacturing a smokeless tobacco product incorporating an object, and associated method
CA2816420C (en) * 2010-10-29 2018-01-16 Najib Babul Compositions of (-)-17-(cyclobutylmethyl)morphinan-3,14-diol
ES2643291T3 (en) * 2010-12-22 2017-11-22 Purdue Pharma L.P. Controlled release dosage forms with inviolable closure coated
CA2822769C (en) 2010-12-23 2016-10-04 Purdue Pharma L.P. Tamper resistant solid oral dosage forms
WO2012166998A1 (en) * 2011-05-31 2012-12-06 QRxPharma Ltd. Compositions for sequential administration of opioid receptor agonists
WO2012170676A1 (en) * 2011-06-08 2012-12-13 Sti Pharma, Llc Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration
CN104105478A (en) 2011-10-28 2014-10-15 维塔利斯公司 Anti-flush compositions
MA37469A1 (en) * 2012-04-30 2016-04-29 Dow Agrosciences Llc Administration vehicles of a pesticide composition
EP2877161A1 (en) 2012-07-06 2015-06-03 Egalet Ltd. Abuse deterrent pharmaceutical compositions for controlled release
JO3464B1 (en) 2013-01-15 2020-07-05 Astellas Pharma Europe Ltd Compositions of Tiacumicin Compounds
KR101840526B1 (en) 2013-02-05 2018-03-20 퍼듀 퍼머 엘피 Tamper resistant pharmaceutical formulations
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
WO2014204933A1 (en) 2013-06-17 2014-12-24 Adamas Pharmaceuticals, Inc. Amantadine compositions and methods of use
CA3042642A1 (en) 2013-08-12 2015-02-19 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
WO2015095644A1 (en) 2013-12-20 2015-06-25 AntiOP, Inc. Intranasal naloxone compositions and methods of making and using same
EP3086789A4 (en) * 2013-12-23 2017-08-02 Purdue Pharma L.P. Opioid antagonist formulations
US20150366814A1 (en) 2014-06-23 2015-12-24 Banner Life Sciences Llc All-natural enteric soft capsules comprising active ingredients
EP3169315B1 (en) 2014-07-17 2020-06-24 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
GB2545368B (en) * 2014-10-20 2021-04-21 Elysium Therapeutics Inc Diversion-resistant opioid formulations
AU2015336065A1 (en) 2014-10-20 2017-05-04 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
US20160157515A1 (en) 2014-12-05 2016-06-09 R.J. Reynolds Tobacco Company Smokeless tobacco pouch
WO2016111731A1 (en) * 2015-01-09 2016-07-14 Banner Life Sciences Llc Abuse-deterrent opioids
BR112017021120A2 (en) * 2015-04-02 2018-07-03 Theravance Biopharma R&D Ip, Llc Combination dosage form of a mu opioid receptor antagonist and an opioid agent
US9766114B2 (en) 2015-08-26 2017-09-19 R.J. Reynolds Tobacco Company Capsule object inspection system and associated method
US10058125B2 (en) 2015-10-13 2018-08-28 Rai Strategic Holdings, Inc. Method for assembling an aerosol delivery device
US20170119680A1 (en) 2015-10-30 2017-05-04 R.P. Scherer Technologies, Llc Extended release film-coated capsules
US10314334B2 (en) 2015-12-10 2019-06-11 R.J. Reynolds Tobacco Company Smoking article
US10285433B2 (en) 2016-01-21 2019-05-14 R.J. Reynolds Tobacco Company Capsule object rupture testing system and associated method
CN109069475B (en) 2016-04-22 2022-01-28 受体控股公司 Fast acting botanical pharmaceutical compounds and nutritional supplements
US10329068B2 (en) 2016-05-23 2019-06-25 R.J. Reynolds Tobacco Company Flavoring mechanism for a tobacco related material
WO2017222575A1 (en) 2016-06-23 2017-12-28 Collegium Pharmaceutical, Inc. Process of making more stable abuse-deterrent oral formulations
BR112019002538A2 (en) 2016-08-11 2019-05-21 Ovid Therapeutics Inc. use of a pharmaceutical composition comprising an allosteric modulator, use of a pharmaceutical composition comprising garboxadol or a pharmaceutically acceptable salt thereof, and pharmaceutical composition for parenteral administration
EA201892396A1 (en) 2016-12-02 2019-04-30 Ресептор Лайф Сайенсиз, Инк. QUICKLY PRODUCTIVE PLANT MEDICINES AND BIOLOGICALLY ACTIVE ADDITIVES
EP3551158A4 (en) * 2016-12-08 2020-06-03 R.P. Scherer Technologies, LLC A method to relieve stress in capsule shells to reduce propensity to break
MX2020002078A (en) 2017-08-24 2020-09-21 Adamas Pharma Llc Amantadine compositions, preparations thereof, and methods of use.
CN111225678A (en) * 2017-10-05 2020-06-02 受体控股公司 Plant and synthetic cannabinoid formulations with rapid onset and prolonged action
US11058143B2 (en) 2017-10-19 2021-07-13 R.J. Reynolds Tobacco Company Smoking-related article inspection systems and associated methods
CA3075292A1 (en) * 2017-10-20 2019-04-25 Purdue Pharma L.P. Pharmaceutical dosage forms
US11266662B2 (en) 2018-12-07 2022-03-08 Marinus Pharmaceuticals, Inc. Ganaxolone for use in prophylaxis and treatment of postpartum depression
KR20220024189A (en) * 2019-06-03 2022-03-03 알.피.쉐러 테크놀러지즈 엘엘씨 Delayed Release Softgel Capsules
CA3145923A1 (en) 2019-08-05 2021-02-11 David Czekai Ganaxolone for use in treatment of status epilepticus
MX2022006014A (en) 2019-12-06 2022-06-22 Marinus Pharmaceuticals Inc Ganaxolone for use in treating tuberous sclerosis complex.
US11872231B2 (en) 2019-12-09 2024-01-16 Nicoventures Trading Limited Moist oral product comprising an active ingredient
US11793230B2 (en) 2019-12-09 2023-10-24 Nicoventures Trading Limited Oral products with improved binding of active ingredients
US11826462B2 (en) 2019-12-09 2023-11-28 Nicoventures Trading Limited Oral product with sustained flavor release
WO2021142288A1 (en) * 2020-01-10 2021-07-15 Trevi Therapeutics, Inc. Methods of administering nalbuphine
WO2023146983A1 (en) * 2022-01-26 2023-08-03 Aardvark Therapeutics, Inc. Liquid resin extended-release oral naltrexone formulation for treating autism-related disorders
WO2024010935A1 (en) * 2022-07-07 2024-01-11 Vitalis Analgesics LLC Compositions of aspirin and ketamine

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3339546A (en) * 1963-12-13 1967-09-05 Squibb & Sons Inc Bandage for adhering to moist surfaces
JPS60120811A (en) * 1983-12-05 1985-06-28 R P Shiila- Kk Soft gelatin capsule
EP0544612A2 (en) * 1991-11-25 1993-06-02 The Nisshin Oil Mills, Ltd. Composition comprising an immunogen and a triglyceride

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4681765A (en) * 1984-09-13 1987-07-21 American Home Products Corporation Rapid releasing triamterene containing gelatin capsule dosage forms for once daily antihypertensive use
ES2043766T3 (en) * 1987-11-11 1994-01-01 Pharmascience Lab A NEW PHARMACEUTICAL COMPOSITION THAT INCLUDES EXIFONE AND A POLYMER SOLUBLE IN WATER.
US5026559A (en) * 1989-04-03 1991-06-25 Kinaform Technology, Inc. Sustained-release pharmaceutical preparation
US5133974A (en) * 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5968551A (en) * 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US6413536B1 (en) * 1995-06-07 2002-07-02 Southern Biosystems, Inc. High viscosity liquid controlled delivery system and medical or surgical device
US5773031A (en) * 1996-02-27 1998-06-30 L. Perrigo Company Acetaminophen sustained-release formulation
WO1997045091A2 (en) * 1996-05-31 1997-12-04 Euro-Celtique, S.A. Sustained release oxycodone formulations with no fed/fast effect
US5986551A (en) * 1997-03-27 1999-11-16 Pueyo; Jacques Method and system for preservation against pesky birds and pest animals
EP0945133A1 (en) * 1998-03-26 1999-09-29 Lipha Combination for the treatment of alcohol and drug dependence containing an opioid antagonist and a NMDA receptor complex modulator
US20010055613A1 (en) * 1998-10-21 2001-12-27 Beth A. Burnside Oral pulsed dose drug delivery system
JP4613275B2 (en) * 1998-11-02 2011-01-12 エラン ファーマ インターナショナル，リミティド Multiparticulate modified release composition
JP2004513091A (en) * 2000-10-03 2004-04-30 ペンウェスト　ファーマシューティカルズ　カンパニー Delivery systems for multiple pharmaceutically active ingredients at different rates
US20030004177A1 (en) * 2001-05-11 2003-01-02 Endo Pharmaceuticals, Inc. Abuse-resistant opioid dosage form
US20030157168A1 (en) * 2001-08-06 2003-08-21 Christopher Breder Sequestered antagonist formulations
US20030191147A1 (en) * 2002-04-09 2003-10-09 Barry Sherman Opioid antagonist compositions and dosage forms
CA2507522C (en) * 2002-12-13 2015-02-24 Durect Corporation Oral drug delivery system

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3339546A (en) * 1963-12-13 1967-09-05 Squibb & Sons Inc Bandage for adhering to moist surfaces
JPS60120811A (en) * 1983-12-05 1985-06-28 R P Shiila- Kk Soft gelatin capsule
EP0544612A2 (en) * 1991-11-25 1993-06-02 The Nisshin Oil Mills, Ltd. Composition comprising an immunogen and a triglyceride

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Section Ch Week 198532, Derwent World Patents Index; Class B07, AN 1985-193549, XP002284488 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8133507B2 (en) 2002-12-13 2012-03-13 Durect Corporation Oral drug delivery system
US8147870B2 (en) 2002-12-13 2012-04-03 Durect Corporation Oral drug delivery system
US8153152B2 (en) 2002-12-13 2012-04-10 Durect Corporation Oral drug delivery system
US8168217B2 (en) 2002-12-13 2012-05-01 Durect Corporation Oral drug delivery system
US9233160B2 (en) 2002-12-13 2016-01-12 Durect Corporation Oral drug delivery system
US9517271B2 (en) 2002-12-13 2016-12-13 Durect Corporation Oral drug delivery system
US9555113B2 (en) 2013-03-15 2017-01-31 Durect Corporation Compositions with a rheological modifier to reduce dissolution variability
US9572885B2 (en) 2013-03-15 2017-02-21 Durect Corporation Compositions with a rheological modifier to reduce dissolution variability

Also Published As

Publication number Publication date
CA2510465A1 (en) 2004-07-08
WO2004056337A2 (en) 2004-07-08
AU2003301121A1 (en) 2004-07-14
US20140193490A1 (en) 2014-07-10
AU2010236049A1 (en) 2010-11-18
EP1572164A2 (en) 2005-09-14
US20110287093A1 (en) 2011-11-24
US20040224020A1 (en) 2004-11-11
US20140186437A1 (en) 2014-07-03
US20080026052A1 (en) 2008-01-31

Similar Documents

Publication Publication Date Title
WO2004056337A3 (en) Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats
NO2020019I1 (en) Maraviroc optionally in the form of a pharmaceutically acceptable salt
NO2017047I1 (en) Tofacitinib, optionally in the form of a pharmaceutically acceptable salt, including citrate salt
MX2009000730A (en) Controlled release formulations and associated methods.
PT1478339E (en) Pharmaceutical formulations of antineoplastic agents, in particular temozolomide, processes of making and using the same
ZA200500734B (en) Microcapsules with modified release of active principles with law solubility for oral delivery
IL183357A0 (en) Oral medicament for the modified release of at least one active principle, in multimicrocapsule form
TR200200562T2 (en) Pharmaceutical compositions for oral release that can be secreted in the body in a controlled manner and prevent unpleasant taste
GB0007419D0 (en) Composition
IL163866A0 (en) 8-Azaprostaglandin derivative compounds and drugs containing the compounds s active ingredient
IL163894A (en) 2-hydroxy-3-heteroarylindole derivatives, pharmaceutical compositions comprising them and their uses in the preparation of medicaments
PL376154A1 (en) Triazaspiro[5.5]undecane derivatives and drugs comprising the same as the active ingredient
IL219671A0 (en) 1,2- benzoxazoles and use thereof in the preparation of a medicament
IL220888A0 (en) 3,10 and 12 a substituted tetracyline compounds, pharmaceutical compositions comprising them and their use in the manufacture of medicaments
AU2003229084A1 (en) Methods and formulations for the delivery of pharmacologically active agents
HRP20050371A2 (en) Administration form for pharmaceutically active peptides with sustained release and method for the production thereof
AU2002335046A1 (en) The use of proton sequestering agents in drug formulations
HRP20010632A2 (en) Matrix tablet enabling prolonged release of gliclazide after administration by the oral route
EP1695699A4 (en) Drug-containing grains and solid preparation containing the grains
DE60131760D1 (en) DEVICE FOR THE ADMINISTRATION OF PHYSIOLOGICALLY ACTIVE ACTIVE IN POWDER FORM
EP1419785A4 (en) Drugs containing chymase inhibitor and ace inhibitor as the active ingredients
EP1602362A4 (en) Drug composition having active ingredient adhered at high concentration to spherical core
AU2001264044A1 (en) 1,4-diazabicyclo(3.2.2)nonabenzoxazole, -benzothiazole and benzimidazole derivatives, preparation and therapeutic use thereof
DE50202227D1 (en) MEDICAMENT CONTAINS AN EFFECTOR OF GLUTATHIONMETABOLISM TOGETHER WITH ALPHA-LIPONIC ACID IN THE CONTEXT OF NURSING-UP THERAPY
IL155853A0 (en) Substituted cyclohexane derivatives and the use thereof in medicaments for treating cardiovascular diseases

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2510465

Country of ref document: CA

Ref document number: 2003301121

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2003813786

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003813786

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Ref document number: JP